Cerenome, Inc.

Stocks

Market Closed - Nasdaq 16:00:00 2026-10-29 EDT			5-day change	1st Jan Change
1.740 ^USD	0.00%		-0.57%	-86.41%

10-29	Cerenome, Inc. Completes Enrollment In Phase 2 ReSPECT-GBM Trial Of REYOBIQ In Recurrent Glioblastoma	CI
10-27	Cerenome, Inc. Presents Interim Clinical Update On The ReSPECT-LM Trial Of Multiple REYOBIQ Doses In Leptomeningeal Metastases	CI

Published on 06/30/2026 at 10:05 am EDT - Modified on 06/30/2026 at 12:36 pm EDT

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Good morning, and welcome to the Plus Therapeutics Midyear 2026 Business Update Conference Call. [Operator Instructions]

Bef

This article is reserved for our subscribers.

Subcribe
to read the article

Unlimited browsing across the entire site

Access to all news and data

US, Europe, and Asia portfolios

Ad-free reading

Pro Tools : expert screeners, historical financials, PDF reports, investment themes, and earnings transcripts

10-29	Cerenome, Inc. Completes Enrollment In Phase 2 ReSPECT-GBM Trial Of REYOBIQ In Recurrent Glioblastoma	CI
10-27	Cerenome, Inc. Presents Interim Clinical Update On The ReSPECT-LM Trial Of Multiple REYOBIQ Doses In Leptomeningeal Metastases	CI
10-21	Cerenome, Inc. Announces New Preclinical Data Illustrating Emerging Immunomodulatory Properties Of REYOBIQ	CI
09-30	Cerenome, Inc. - Special Call
09-10	Cerenome, Inc. Enters Into Up To $20 Million Senior Secured Financing Facility With 3i, LP With Royalty-Based Repayment	CI
09-03	Cerenome, Inc. announced that it expects to receive $20 million in funding from 3i Fund	CI
08-14	Cerenome, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-02	Plus Therapeutics, Inc. will Change its Name to Cerenome	CI
08-02	Plus Therapeutics, Inc. will Change its Ticker to CNSY from PSTV	CI
07-16	Plus Therapeutics, Inc. And Genomic Testing Cooperative, LCA Partner To Integrate Next-Generation Sequencing Into The CNSide CSF Assay Platform	CI
07-16	Plus Therapeutics, Genomic Testing Cooperative to Integrate NGS Technology Into CNSide CSF Assay Platform	MT
07-14	Plus Therapeutics, Inc. Highlights Updated NCCN CNS Cancers Guidelines and Reinforces Clinical Role of CNSide in Leptomeningeal Metastases Monitoring	CI
06-30	Plus Therapeutics, Inc. - Special Call
06-30	Plus Therapeutics Advances REYOBIQ Clinical Trials and Manufacturing Progress	CI
06-29	Plus Therapeutics, Inc.(NasdaqCM:PSTV) added to Russell 3000E Index	CI

Duration

Period

Sector